A5054068185- Health Systems, Economic Evaluations, Quality of Life
- Neutropenia and Cancer Infections
- Lipoproteins and Cardiovascular Health
- Public Health in Brazil
- Pharmaceutical Practices and Patient Outcomes
- Antibiotic Use and Resistance
- Health Education and Validation
- Frailty in Older Adults
- Healthcare during COVID-19 Pandemic
- Medication Adherence and Compliance
- Urinary Tract Infections Management
- Cancer survivorship and care
- Pharmaceutical Economics and Policy
- Bacterial Identification and Susceptibility Testing
Amgen (United States)
2021
Universidad de La Sabana
2017
Abstract Background Febrile neutropenia associated with some chemotherapy regimens can lead to potentially fatal complications and high health care costs. Administration of pegfilgrastim using an On-Body Injector (OBI) may be more convenient for cancer patients physicians in countries limited access high-complexity healthcare. This study aims describe physician nurse preferences regarding different options administration at centers, the schemes which is most frequently prescribed how...
Cardiovascular disease (CVD) represents the primary cause of death and disability globally, with elevated cholesterol as one leading risk factors for CVD. We describe clinical characteristics, treatment patterns, effectiveness evolocumab in treating hyperlipidemia. Observational study conducted through a chart review patients hyperlipidemia receiving part management Colombia. This included 115 treated evolocumab. A total 101 (87.8%) had history CVD, 13 (11.3%) familial hypercholesterolemia...
Cardiovascular disease (CVD) represents the primary cause of death and disability globally, with elevated cholesterol as one leading risk factors for CVD. We describe clinical characteristics, treatment patterns, effectiveness evolocumab in treating hyperlipidemia. Observational study conducted through a chart review patients hyperlipidemia receiving part management Colombia. This included 115 treated evolocumab. A total 101 (87.8%) had history CVD, 13 (11.3%) familial hypercholesterolemia...
Abstract Purpose Febrile neutropenia associated with some chemotherapy regimens can lead to potentially fatal complications and high health care costs. Administration of Pegfilgrastim 27 hours after chemotherapy, using an On-Body Injector (OBI), may be more convenient for cancer patients physicians. This study aims describe physician nurse preferences regarding options administration at centers, the demographics population characteristics participating centers. We aim determine conditions...